Vaccines have helped greatly reduce the rate of invasive meningococcal disease among adolescents over the past 20 years, and the new formulation that covers all main types of the bacteria could help improve vaccination coverage and drive infection rates even lower, reported the researchers led by senior author Gregory Zimet from the department of pediatrics at the Indiana University School of Medicine in Indianapolis, Indiana.
Before the introduction of vaccines in 2005, the incidence of disease in the United States ranged from 0.5-1.1 cases per 100,000 people, with ≥ 10% of cases being fatal.In 2005, the first quadrivalent meningococcal vaccine, covering serogroups ACWY, was approved in the United States and recommended for routine use in 11- and 12-year-olds, followed by a 2010 booster recommendation at age 16 years.
The B vaccine has been less successful, reported the researchers, who said this is likely because uptake was much lower due to it not being part of the routine schedule.
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: NPRHealth - 🏆 144. / 63 Read more »